Clinical trials: Enoxaparin
Obesity
Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity
Approximately two thirds of the adult population in developed countries is categorized as over-weight or obese (BMI>30). In spite of worldwide increasing awareness, obesity is a major health concern.
- Trial name
- NCT01970202
- Testing
- 40mg Enoxaparin, 60mg Enoxaparin, Control
- Where
- Israel
- Volunteers
- 55 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hemodialysis Patients
Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients.
The aim of the study is to evaluate the effect of Enoxaparin (LMWH) on the incidence of AV graft thromboses in patients on chronic hemodialysis.
- Trial name
- NCT01970280
- Testing
- Enoxaparin
- Where
- 2 sites in Israel
- Volunteers
- 26 people
- Sponsor
- Dr. Sidney Ben Chetrit
This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.
Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism
Purpose and rationale: Acute pulmonary embolism (PE) is a common and often fatal disease, with an approximately 30% mortality rate without treatment. Treatment is important to reduce mortality and recurrence in acute PE.
- Trial name
- NCT01956955
- Testing
- enoxaparin ,alteplase, unfractionated heparin
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Ataturk University
Pancreatic Cancer
Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer
Venous thromboembolic events are considered to be a prognostic negative factor and small studies showed astonishing survival advantages using heparin as prophylactic treatment to prevent venous thromboembolic events.
- Trial name
- NCT01945879
- Testing
- Enoxaparine
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- CONKO-Studiengruppe
Asymptotic Venous Thrombosis
Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery
The CATCH-enoxaparin trial is the natural continuation of the CATCH study. It will capitalize on the fact that patients enrolled in the CATCH study will be specifically screened for asymptomatic thromboembolism (TEs) in order to…
- Trial name
- NCT01474902
- Testing
- Enoxaparin
- Where
- Canada
- Sponsor
- The Hospital for Sick Children
Pregnancy, Miscarriage
Aspirin, Heparin and Miscarriage
Efficacy of low dose aspirin (LDA) versus LDA plus low-molecular-weight-heparin (LMWH) in patients with a history of recurrent miscarriages.
- Trial name
- NCT01917799
- Testing
- Aspirin, Heparin
- Where
- Libya
- Volunteers
- 150 people
- Sponsor
- University of Khartoum
Non-Small Cell Lung Cancer
Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)
Rationale: a number of recent phase III randomized trials have shown a survival benefit of a treatment with subcutaneous low-molecular weight heparin in patients with advanced solid malignancies.
- Trial name
- SYRINGES (NCT00771563)
- Testing
- cisplatin + docetaxel, cisplatin + docetaxel + enoxaparin
- Where
- 2 sites in Belgium
- Volunteers
- 104 people
- Sponsor
- University Hospital, Antwerp
Deep Vein Thrombosis
The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.
The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane on the development of leg clots following electrophysiology studies (EPS) and or radiofrequency ablation (RFA).
- Trial name
- NCT00232271
- Testing
- Clexane
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Melbourne Health
Lower Extremity Deep Venous Thrombosis
Comparison of Subcutaneous Heparin and Enoxaparin for Deep Venous Thrombosis (DVT) Prophylaxis in Surgical Intensive Care Patients
Study hypothesis: Subcutaneous enoxaparin is more effective than subcutaneous heparin in preventing the development of DVT in the general surgical intensive care unit population.
- Trial name
- NCT01325779
- Testing
- heparin, enoxaparin
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Lisa Louwers
Small Cell Lung Cancer
A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
The purpose of this research study is to see if adding enoxaparin sodium to standard treatment with the chemotherapy drugs cisplatin and etoposide will help treat extensive stage SCLC.
- Trial name
- NCT00916669
- Testing
- Etoposide, Cisplatin, enoxaparin sodium
- Where
- 4 sites in United States
- Sponsor
- Massachusetts General Hospital
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
The primary objective was to compare the efficacy of once daily [q.d.] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP1 (NCT00697099)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 2,326 people
- Sponsor
- Sanofi
Venous Thromboembolism
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-VEMED (NCT00714597)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 421 people
- Sponsor
- Sanofi
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
The primary objective was to compare the efficacy of Semuloparin sodium (AVE5026) with Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing elective knee replacement surgery.
- Trial name
- SAVE-KNEE (NCT00718224)
- Testing
- Semuloparin sodium, Enoxaparin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,150 people
- Sponsor
- Sanofi
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP2 (NCT00721760)
- Testing
- Enoxaparin sodium, Semuloparin sodium
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery.
- Trial name
- TREK (NCT00331838)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 19 sites in Argentina, Bulgaria and 17 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Primary PCI - STEMI
STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)
Randomized evaluation of enoxaparin (0.5mg/kg IV) versus UFH (50-70IU/kg with GPIIb/IIIa inhibitors; 70-100IU without GPIIb/IIIa inhibitors).
- Trial name
- ATOLL (NCT00718471)
- Testing
- Enoxaparin, UFH (unfractionated heparin)
- Where
- France
- Volunteers
- 910 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thromboembolism
Thromboprophylaxis and Bariatric Surgery
This trial is an assessment of the efficacy of three thromboprophylaxis regimens in two types of bariatric surgery. gastric banding and gastric bypass on anti-Xa activity levels The study includes two groups of 150 patients…
- Trial name
- NCT00444652
- Testing
- Enoxaparin
- Where
- 10 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Acute Myocardial Infarction
The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study
The purpose of this study is to assess the safety and efficacy of Enoxaparin and Unfractionated Heparin in St Elevation Myocardial Infarction patients undergoing primary percutaneous coronary intervention.
- Trial name
- NCT00882635
- Testing
- enoxaparin, Unfractionated heparin
- Where
- 2 sites in Canada
- Volunteers
- 44 people
- Sponsor
- Robert Welsh
Thrombosis
Study of Blood Clotting After Transcatheter Atrial Septal Defect Closure
The purpose of this study is to evaluate blood clots after Percutaneous ASD Closure in different age, sexuality and defective diameter; evaluating the relationship of blood clotting with Occluder, injury of intima and…
- Trial name
- NCT01086046
- Testing
- Low molecular weight heparin
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Thromboembolism
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery
- Trial name
- PEARL-1 (NCT00408239)
- Testing
- YM150, enoxaparin
- Where
- 19 sites in Indonesia, Japan and 6 more
- Volunteers
- 367 people
- Sponsor
- Astellas Pharma Inc